Clinical trial
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With…
NCT00099242 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099242 |
|---|---|
| Title | Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease |
| Official title | Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease, Dementia, Alzheimer Type |
| Intervention type | Drug |
| Interventions | rivastigmine transdermal patch |
| Enrollment | 1,040 |
| Start date | Nov 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Dec 10, 2004 |
| Last update posted | Oct 13, 2017 |
| Countries | Chile, Czechia, Denmark, Finland, Germany, Guatemala, Israel, Italy, Mexico, Norway, Peru, Poland and 9 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: